Cargando…

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa

Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa. This was a retrospective cohort study of patients receiving Dlm-containing treatment regimens between November 2015 and Aug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohr, Erika, Hughes, Jennifer, Reuter, Anja, Trivino Duran, Laura, Ferlazzo, Gabriella, Daniels, Johnny, De Azevedo, Virginia, Kock, Yulene, Steele, Sarah Jane, Shroufi, Amir, Ade, Serge, Alikhanova, Natavan, Benedetti, Guido, Edwards, Jeffrey, Cox, Helen, Furin, Jennifer, Isaakidis, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485275/ https://www.ncbi.nlm.nih.gov/pubmed/29724920 http://dx.doi.org/10.1183/13993003.00017-2018

Ejemplares similares

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa
por: Reuter, Anja, et al.
Publicado: (2022)

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting
por: Mohr, Erika, et al.
Publicado: (2017)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

“Life continues”: Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household
por: Apolisi, Ivy, et al.
Publicado: (2023)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

“This is not my body”: Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis
por: Loveday, Marian, et al.
Publicado: (2021)

Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis
por: Reuter, Anja, et al.
Publicado: (2023)

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
por: Mohr-Holland, E., et al.
Publicado: (2021)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients
por: Mohr-Holland, E., et al.
Publicado: (2021)

Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
por: Tack, Ilse, et al.
Publicado: (2020)

Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients
por: Acquah, Rebecca, et al.
Publicado: (2021)

Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
por: Cox, Helen, et al.
Publicado: (2022)

“Take the treatment and be brave”: Care experiences of pregnant women with rifampicin-resistant tuberculosis
por: Loveday, Marian, et al.
Publicado: (2020)

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic
por: Mohr-Holland, Erika, et al.
Publicado: (2021)

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study
por: Cox, Helen, et al.
Publicado: (2021)

Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?
por: Benbaba, Stella, et al.
Publicado: (2015)

How COVID-19 could benefit tuberculosis and HIV services in South Africa
por: Keene, Claire, et al.
Publicado: (2020)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success
por: Daniels, Johnny Flippie, et al.
Publicado: (2015)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India
por: Isaakidis, Petros, et al.
Publicado: (2013)

Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa
por: Cox, Helen S., et al.
Publicado: (2015)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2016)

Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa
por: Moyo, Sizulu, et al.
Publicado: (2015)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Delamanid expanded access novel treatment of drug resistant tuberculosis
por: Rustomjee, Roxana, et al.
Publicado: (2015)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
por: Marwah, Vikas, et al.
Publicado: (2023)

“A very humiliating illness”: a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa
por: Furin, Jennifer, et al.
Publicado: (2020)

Investigating the addition of oral HIV self-tests among populations with high testing coverage – Do they add value? Lessons from a study in Khayelitsha, South Africa
por: Moore, Hazel Ann, et al.
Publicado: (2019)

Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods
por: You, Shiying, et al.
Publicado: (2022)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pdct0pn11jh3echma7kd0lq6bv